 |
市場調查報告書
商品編碼
1489236
全球急性間歇性卟啉症市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測Global Acute Intermittent Porphyria Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
全球急性間歇性卟啉症市場需求預計將從 2023 年的 563 萬美元達到 2032 年近 841 萬美元的市場規模，2024-2032 年研究期間複合年成長率為 4.56%。
急性間歇性卟啉症 (AIP) 是一種罕見的遺傳性疾病，會影響血紅素（血紅素的一種成分）的產生。突然發作的腹痛、嘔吐、神經系統失調以及焦慮或幻覺等心理症狀是其特徵。某些藥物、荷爾蒙變化或飲食因素通常會引發這些發作。診斷包括檢測尿液中膽色素原和δ-氨基乙醯丙酸水平升高。治療包括避免誘發因素、發作期間的症狀治療，有時還需要使用血紅素輸注。
市場動態
急性間歇性卟啉症市場受到對罕見遺傳性疾病的認知和診斷不斷提高的影響，從而改善了疾病管理和治療選擇。此外，醫學研究和基因檢測技術的進步使醫療保健提供者能夠更好地了解急性間歇性卟啉症的根本原因和機制，從而促進早期檢測和介入。此外，製藥公司和學術機構之間的合作推動了研發工作，以發現新療法並改善治療選擇。然而，有限的治療選擇和管理急性發作的複雜性等挑戰可能會影響未來幾年的市場成長。隨著醫療保健提供者和研究人員努力為罕見疾病患者提供更好的治療結果和生活品質，對急性間歇性卟啉症的有效治療和管理策略的需求預計將推動市場的進一步發展。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球急性間歇性卟啉症市場的各個細分市場進行了包容性評估。急性間歇性卟啉症產業的成長和趨勢為本研究提供了整體方法。
市場區隔
急性間歇性卟啉症市場報告的這一部分提供了有關國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。
透過診斷
- 驗血
- 尿液檢查
- 脫氧核糖核酸測試
- 血清檢測
按治療
- 促性腺激素釋放激素類似物
- 預防性血紅素輸注
按最終用戶
- 醫院
- 診所
- 研究中心
區域分析
本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的急性間歇性卟啉症市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。急性間歇性卟啉症市場的主要參與者包括 Alnylam Pharmaceuticals Inc.、Clinuvel Pharmaceuticals Ltd.、BioMarin Pharmaceutical Inc.、Recordati、Quest Diagnostics、Invitae Corp.、Laboratory Corporation Of America Holdings (Labcorp) 和 ARUP Laboratories。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
目錄
第1章：前言
- 報告說明
- 客觀的
- 目標受眾
- 獨特的銷售主張 (USP) 和產品
- 研究範圍
- 研究方法論
- 市場研究過程
- 市場研究方法論
第 2 章：執行摘要
- 市場亮點
- 全球市場概況
第 3 章：急性間歇性卟啉症 - 產業分析
- 簡介 - 市場動態
- 市場促進因素
- 市場限制
- 機會
- 產業動態
- 波特五力分析
- 市場吸引力分析
- 市場吸引力診斷分析
- 按處理方式進行的市場吸引力分析
- 最終用戶的市場吸引力分析
- 市場吸引力分析：按地區
第 4 章：價值鏈分析
- 價值鏈分析
- 原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
- 潛在買家名單
- 行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢
第 5 章：全球急性間歇性卟啉症市場分析：透過診斷
- 診斷概述
- 歷史和預測數據
- 診斷分析
- 驗血
- 尿液檢查
- 脫氧核糖核酸測試
- 血清檢測
第 6 章：全球急性間歇性卟啉症市場分析：依治療分類
- 按治療概述
- 歷史和預測數據
- 治療分析
- 促性腺激素釋放激素類似物
- 預防性血紅素輸注
第 7 章：全球急性間歇性卟啉症市場分析：依最終使用者分類
- 最終用戶概述
- 歷史和預測數據
- 最終用戶分析
- 醫院
- 診所
- 研究中心
第 8 章：全球急性間歇性卟啉症市場分析：依地理位置
- 區域展望
- 介紹
- 北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
- 歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
- 亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
- 拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
- 中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析
第 9 章：急性間歇性卟啉症公司的競爭格局
- 急性間歇性卟啉症市場競爭
- 夥伴關係/協作/協議
- 併購
- 新產品發布
- 其他發展
第 10 章：公司簡介
- 頂級公司市佔率分析
- 市場集中度
- Alnylam Pharmaceuticals Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Clinuvel Pharmaceuticals Ltd.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- BioMarin Pharmaceutical Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Recordati
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Quest Diagnostics
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Invitae Corp.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Laboratory Corporation Of America Holdings (Labcorp)
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- ARUP Laboratories
- 公司簡介
- 公司收入
- 產品
- 最近的發展
註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內
The global demand for Acute Intermittent Porphyria Market is presumed to reach the market size of nearly USD 8.41 Million by 2032 from USD 5.63 Million in 2023 with a CAGR of 4.56% under the study period 2024-2032.
Acute intermittent porphyria (AIP) is a rare genetic disorder that affects heme production, a hemoglobin component. Sudden attacks of abdominal pain, vomiting, neurological disturbances, and psychological symptoms like anxiety or hallucinations characterize it. Certain medications, hormonal changes, or dietary factors often trigger these attacks. Diagnosis involves detecting elevated levels of porphobilinogen and delta-aminolevulinic acid in the urine. Management includes avoiding triggers, symptomatic treatment during attacks, and sometimes the use of heme infusions.
MARKET DYNAMICS
The acute intermittent porphyria market is influenced by the increasing awareness and diagnosis of rare genetic disorders, leading to improved disease management and treatment options. Additionally, advancements in medical research & genetic testing technologies enable healthcare providers to understand better the underlying causes and mechanisms of acute intermittent porphyria, facilitating earlier detection and intervention. Moreover, collaborations among pharmaceutical companies and academic institutions drive research & development efforts to discover novel therapies and improve treatment options. However, challenges such as limited treatment options and the complexity of managing acute attacks may impact the market growth in the coming years. As healthcare providers and researchers strive for better outcomes and quality of life for patients with rare diseases, the demand for effective treatments and management strategies for acute intermittent porphyria is expected to drive further market development.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Intermittent Porphyria. The growth and trends of Acute Intermittent Porphyria industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Acute Intermittent Porphyria market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Diagnosis
- Blood Test
- Urine Test
- DNA Test
- Serum Test
By Treatment
- Gonadotropin-Releasing Hormone Analogues
- Prophylactic Hematin Infusions
By End-user
- Hospitals
- Clinics
- Research Centers
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Acute Intermittent Porphyria market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Intermittent Porphyria market include Alnylam Pharmaceuticals Inc., Clinuvel Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Recordati, Quest Diagnostics, Invitae Corp., Laboratory Corporation Of America Holdings (Labcorp), ARUP Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. ACUTE INTERMITTENT PORPHYRIA - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Diagnosis
- 3.7.2 Market Attractiveness Analysis By Treatment
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY DIAGNOSIS
- 5.1. Overview By Diagnosis
- 5.2. Historical and Forecast Data
- 5.3. Analysis By Diagnosis
- 5.4. Blood Test Historic and Forecast Sales By Regions
- 5.5. Urine Test Historic and Forecast Sales By Regions
- 5.6. DNA Test Historic and Forecast Sales By Regions
- 5.7. Serum Test Historic and Forecast Sales By Regions
6. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY TREATMENT
- 6.1. Overview By Treatment
- 6.2. Historical and Forecast Data
- 6.3. Analysis By Treatment
- 6.4. Gonadotropin-Releasing Hormone Analogues Historic and Forecast Sales By Regions
- 6.5. Prophylactic Hematin Infusions Historic and Forecast Sales By Regions
7. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY END-USER
- 7.1. Overview By End-user
- 7.2. Historical and Forecast Data
- 7.3. Analysis By End-user
- 7.4. Hospitals Historic and Forecast Sales By Regions
- 7.5. Clinics Historic and Forecast Sales By Regions
- 7.6. Research Centers Historic and Forecast Sales By Regions
8. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ACUTE INTERMITTENT PORPHYRIA COMPANIES
- 9.1. Acute Intermittent Porphyria Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF ACUTE INTERMITTENT PORPHYRIA INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Alnylam Pharmaceuticals Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Clinuvel Pharmaceuticals Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. BioMarin Pharmaceutical Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Recordati
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. Quest Diagnostics
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Invitae Corp.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Laboratory Corporation Of America Holdings (Labcorp)
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. ARUP Laboratories
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Diagnosis (USD MN)
- Blood Test Market Sales By Geography (USD MN)
- Urine Test Market Sales By Geography (USD MN)
- DNA Test Market Sales By Geography (USD MN)
- Serum Test Market Sales By Geography (USD MN)
- Analysis By Treatment (USD MN)
- Gonadotropin-Releasing Hormone Analogues Market Sales By Geography (USD MN)
- Prophylactic Hematin Infusions Market Sales By Geography (USD MN)
- Analysis By End-user (USD MN)
- Hospitals Market Sales By Geography (USD MN)
- Clinics Market Sales By Geography (USD MN)
- Research Centers Market Sales By Geography (USD MN)
- Global Acute Intermittent Porphyria Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Acute Intermittent Porphyria Report
- Market Research Process
- Market Research Methodology
- Global Acute Intermittent Porphyria Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Diagnosis
- Market Attractiveness Analysis By Treatment
- Market Attractiveness Analysis By End-user
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Diagnosis (USD MN)
- Blood Test Market Sales By Geography (USD MN)
- Urine Test Market Sales By Geography (USD MN)
- DNA Test Market Sales By Geography (USD MN)
- Serum Test Market Sales By Geography (USD MN)
- Global Market Analysis By Treatment (USD MN)
- Gonadotropin-Releasing Hormone Analogues Market Sales By Geography (USD MN)
- Prophylactic Hematin Infusions Market Sales By Geography (USD MN)
- Global Market Analysis By End-user (USD MN)
- Hospitals Market Sales By Geography (USD MN)
- Clinics Market Sales By Geography (USD MN)
- Research Centers Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
急性間歇性紫質症市場規模、佔有率、成長分析（按診斷、按治療、按最終用戶、按地區）- 2025 年至 2032 年產業預測
急性間歇性卟啉症市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034 年